Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634154 | 0.85 | TAAR1 (0.50) | TAAR1KIF11KCNN4HDAC3HDAC1 | |
| SCHEMBL8805196 | 0.85 | TAAR1 (0.50) | TAAR1KIF11KCNN4HDAC3HDAC1 | |
| SCHEMBL18387167 | 0.83 | ACHE (0.34) | KIF11KCNN4HDAC3HDAC1HDAC2 | |
| SCHEMBL24702447 | 0.80 | TAAR1 (0.45) | TAAR1KIF11KCNN4KCNE1KCNQ1 | |
| SCHEMBL779068 | 0.78 | RIPK1 (0.39) | KIF11KCNN4HDAC3HDAC1HDAC2 | |
| SCHEMBL22435799 | 0.77 | CNR2 (0.41) | — | |
| SCHEMBL3508754 | 0.77 | SLC22A12 (0.37) | KCNN4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL2139453 | 0.77 | KCNN4 (0.39) | KCNN4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL13591348 | 0.77 | SHBG (0.38) | KIF11KCNN4HDAC3HDAC1HDAC2 | |
| SCHEMBL24121391 | 0.76 | IDO1 (0.36) | TAAR1HTR2CHTR2BRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | TAAR1 3381/4885KIF11 4459/4885KCNN4 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.